TaperCommunityvenlafaxine
Boxed Warning
Suicidality risk in children, adolescents, and young adults under 25 during initial treatment.
Venlafaxine is an SNRI approved for major depressive disorder, generalized anxiety disorder, social anxiety disorder, and panic disorder. It is well known for having one of the most challenging discontinuation syndromes among antidepressants.
37.5mg, 75mg, 150mg, 225mg
Extended-release capsules (XR): 37.5mg, 75mg, 150mg; Immediate-release tablets: 25mg, 37.5mg, 50mg, 75mg, 100mg
Category C (risk cannot be ruled out)
Serotonin-norepinephrine reuptake inhibitor (SNRI). At lower doses primarily inhibits serotonin reuptake; norepinephrine reuptake inhibition becomes more prominent at doses ≥150mg. Weak dopamine reuptake inhibition at high doses.
Very short half-life makes this one of the hardest drugs to taper. Bead counting from capsules gives precise dose control.
Extremely slow taper essential due to short half-life. Bead counting recommended. Some clinicians bridge with fluoxetine (longer half-life) for final discontinuation.
Evidence-based phased reduction schedule. Always taper under medical supervision.
| Phase | Duration | Notes |
|---|---|---|
| Initial reductions | 4-6 weeks | Use available capsule strengths. XR capsules should not be split. |
| Middle reductions | 6-8 weeks | Withdrawal often intensifies in this phase. Your prescriber may use intermediate steps. |
| Lower dose reductions | 6-8 weeks | Ask your prescriber about bead counting from XR capsules for more precise adjustments. |
| Final reductions | 10-16 weeks | Extremely gradual approach needed. Some prescribers use a fluoxetine bridge strategy for this phase. |
6-12 hours after missed dose (extremely fast due to 5hr half-life)
2-4 days
2-4 weeks for acute symptoms
Brain zaps, emotional volatility, and vertigo can persist 2-6 months. Effexor is widely regarded as having the most severe SNRI withdrawal.
Practical insights shared by members tapering Effexor. Not medical advice — always consult your prescriber.
Toxicity
Serotonin syndrome. Sustained hypertension at higher doses. Seizures in overdose. Discontinuation syndrome is among the most severe of all antidepressants.
Pharmacokinetics
Well absorbed orally (~92%). Extensive first-pass metabolism; bioavailability ~45%. Tmax 2 hours (IR), 5.5 hours (XR). Food slightly delays but does not affect extent of absorption.
~7.5 L/kg
Hepatic primarily via CYP2D6 to the active metabolite O-desmethylvenlafaxine (desvenlafaxine). CYP3A4 contributes to N-desmethylvenlafaxine (less active).
Renal (~87%, with ~5% as unchanged venlafaxine and ~29% as desvenlafaxine). Fecal minimal.
~27% (venlafaxine), ~30% (O-desmethylvenlafaxine)
~1.3 L/hr/kg (venlafaxine), ~0.4 L/hr/kg (desvenlafaxine)
Browse our map of deprescribing-informed providers worldwide.